Last Updated: 30/01/2023

Safety, tolerability, immunogenicity and protective efficacy of PfSPZ vaccine and PfSPZ-CVac in Indonesian adults against naturally-transmitted malaria

Objectives

To assess the safety, tolerability, immunogenicity and protective efficacy of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring malaria in 372 healthy Indonesian soldiers aged 18-55 years who will be deployed in malarious eastern Indonesia.

Principal Institution

University of Indonesia, Indonesia

Principal Investigators / Focal Persons

Erni Juwita Nelwan

Study Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Prevention

ClinicalTrials.gov Identifier: NCT03503058

Date

May 2022 — Jul 2023

Funding Details
Sanaria, United States

Grant ID: IDSPZV1
Project Site

Indonesia

SHARE
SHARE